2025, Vol. 8, Issue 1, Part A

Methods: Total 40 patients <18 years of age diagnosed with HL at BSH&I from January 2018 to 2024 were enrolled. Staging, demographic findings, treatment protocols and outcomes were studied and analyzed for possible correlation between various parameters.

Results: In our study, the mean age of patients was 9.9 years (SD±3.8), and included 60% (n 18) male and 40% (n 12) female patients. Fifty percent of patients were treated with ABVD protocol and 50% with BEACOPP protocol. There was a significant association between coughing as a symptom and high stage of the disease (p 0.042). The 5-year event-free survival (EFS) and overall survival (OS) rate for patients in low-risk group were better than intermediate and high-risk group.

Conclusion: Treatment modalities based on staging is important for improving outcomes in HL. In the limited settings, ABVD and other treatment protocols supplemented with BMT in relapsed cases is associated with good outcomes.